✦ LIBER ✦

Defining the standard of care: Randomized controlled trials for the treatment of hepatitis C in the HIV-infected person

✍ Scribed by Mark S. Sulkowski

Publisher: John Wiley and Sons
Year: 2004
Tongue: English
Weight: 56 KB
Volume: 39
Category: Article
ISSN: 0270-9139
DOI: 10.1002/hep.20191

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Randomized Controlled Trial of Quinacrin

Randomized Controlled Trial of Quinacrine for the Treatment of HBsAg-Positive Chronic Hepatitis

✍ Henry C. Bodenheimer Jr.; Fenton Schaffner; Salvatore Vernace; Shalom Z. Hirschm 📂 Article 📅 2007 🏛 John Wiley and Sons 🌐 English ⚖ 389 KB 👁 1 views

Several drugs which react with DNA decrease hepatitis B viral (HBV) DNA polymerase activity in vitro. Because such an alteration of viral replication, if produced in patients with hepatitis B surface antigen (HBsAg)-positive chronic hepatitis, may lead to elimination of viral infection, we conducted

(+)-Cyanidanol-3 in the Treatment of Acu

(+)-Cyanidanol-3 in the Treatment of Acute Viral Hepatitis: A Randomized Controlled Trial

✍ Hans Schomerus; Karl H. Wiedmann; Wolfgang Dölle; Herrmann Peerenboom; Georg Str 📂 Article 📅 1984 🏛 John Wiley and Sons 🌐 English ⚖ 461 KB 👁 1 views

One-hundred sixty patients (81 cyanidanol, 79 placebo) were included in a double-blind placebo-controlled clinical trial to evaluate the effect of 3 gm (+)-cyanidanol-3 per day for 8 weeks on the clinical course of acute viral hepatitis and HBsAg elimination. Quantitative determination of HBsAg was

Combination therapy with thymosin α1 and

Combination therapy with thymosin α1 and interferon for the treatment of chronic hepatitis C infection: A randomized, placebo-controlled double-blind trial

✍ Kenneth E. Sherman; Maria Sjogren; Robin L. Creager; Melissa A. Damiano; Stephen 📂 Article 📅 1998 🏛 John Wiley and Sons 🌐 English ⚖ 111 KB 👁 1 views

Hepatitis C is a major cause of liver disease leading to cirrhosis. Although interferon (IFN) is the only approved therapy, treatment is characterized by low response rates and dose-limiting side effects. We evaluated the addition of thymosin ␣1 (TA1), an immunomodulatory peptide, to the standard tr

Response-guided peg-interferon plus riba

Response-guided peg-interferon plus ribavirin treatment duration in chronic hepatitis C: Meta-analyses of randomized, controlled trials and implications for the future

✍ Vincent Di Martino; Carine Richou; Jean-Paul Cervoni; Jose M. Sanchez-Tapias; Do 📂 Article 📅 2011 🏛 John Wiley and Sons 🌐 English ⚖ 333 KB 👁 1 views

Response-guided pegylated interferon (peg-IFN) plus ribavirin (P/R) therapy trials on genotype (G)1 and G2/G3 hepatitis C virus-infected patients provide contradictory results. We conducted meta-analyses of randomized, controlled trials to address (1) the benefit of a 72-week extended-duration thera

Meta-analysis of interferon randomized t

Meta-analysis of interferon randomized trials in the treatment of viral hepatitis C: Effects of dose and duration

✍ T Poynard; V Leroy; M Cohard; T Thevenot; P Mathurin; P Opolon; J P Zarski 📂 Article 📅 1996 🏛 John Wiley and Sons 🌐 English ⚖ 362 KB 👁 2 views

The aims of this study were to evaluate the benefits usual dose and duration, that is, at 3 MU three times per of higher doses or of longer duration in comparison with week for 6 months, versus a control group in terms of alanine a standard interferon regimen (3 MU three times per transaminase (ALT)

Randomized controlled trial of modafinil

Randomized controlled trial of modafinil for the treatment of fatigue in postpolio patients

✍ K. Ming Chan; Fay J. Strohschein; David Rydz; Amyn Allidina; Ashfaq Shuaib; Chri 📂 Article 📅 2005 🏛 John Wiley and Sons 🌐 English ⚖ 86 KB 👁 1 views

## Abstract The purpose of this study was to test whether modafinil is effective in alleviating the symptoms of fatigue in postpolio patients, because it has been helpful for such symptoms in other neurologic disorders. Using a double‐blind, randomized, placebo‐controlled cross‐over design, 14 post